|Mr. Gunupati Venkateswara Prasad B.Sc. (Chem. Eng.), M.S. (Indl. Admn.)||Co-Chairman, MD & CEO||97.74M||N/A||58|
|Mr. Kallam Satish Reddy B.Tech., M.S.||Chairman||72.44M||N/A||51|
|Mr. Saumen Chakraborty B.Sc. (H), MBA-IIM||Pres, CFO and Global Head of Information Technology & Bus. Process Excellence||N/A||N/A||57|
|Dr. Sripada Chandrasekhar Mba., Ph.D.||Pres & Global Head of HR||22.1M||N/A||61|
|Mr. Abhijit Mukherjee B.Tech. (Chem.)||Chief Operating Officer||N/A||N/A||60|
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2017, this segment had 16 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies; and strategic collaboration with Amgen Inc. for the commercialization of oncology and osteoporosis medicines. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
Dr. Reddy's Laboratories Limited’s ISS governance QualityScore as of 1 January 2018 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder rights: 1; Compensation: 9.